相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Prognostic impact of lipoprotein (a) on long-term clinical outcomes in diabetic patients on statin treatment after percutaneous coronary intervention
Norihito Takahashi et al.
JOURNAL OF CARDIOLOGY (2020)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A. Bittner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease
Jonathan Golledge et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials
Kausik K. Ray et al.
ATHEROSCLEROSIS (2019)
Strategies to Overcome Residual Risk During Statins Era
Kyoung Im Cho et al.
CIRCULATION JOURNAL (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2019)
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia
Olga I. Afanasieva et al.
ATHEROSCLEROSIS (2018)
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Marc P. Bonaca et al.
CIRCULATION (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Marie D. Gerhard-Herman et al.
CIRCULATION (2017)
Usefulness of Lipoprotein(a) for Predicting Clinical Outcomes After Endovascular Therapy for Aortoiliac Atherosclerotic Lesions
Keiichi Hishikari et al.
JOURNAL OF ENDOVASCULAR THERAPY (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Robert P. Giugliano et al.
LANCET (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS
Alberico L. Catapano et al.
RUSSIAN JOURNAL OF CARDIOLOGY (2017)
Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity
S. N. Pokrovsky et al.
ATHEROSCLEROSIS SUPPLEMENTS (2017)
Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States
Steve Varvel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
Todd J. Anderson et al.
CANADIAN JOURNAL OF CARDIOLOGY (2016)
Heart Disease and Stroke Statistics-2015 Update A Report From the American Heart Association
Dariush Mozaffarian et al.
CIRCULATION (2015)
Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting
Marat V. Ezhov et al.
ATHEROSCLEROSIS (2014)
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Amit V. Khera et al.
CIRCULATION (2014)
Plasma Lipoprotein(a) Concentration Predicts Future Coronary and Cardiovascular Events in Patients With Stable Coronary Heart Disease
Paul J. Nestel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography
Maya S. Safarova et al.
ATHEROSCLEROSIS SUPPLEMENTS (2013)
Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes)
John J. Albers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
Deepak L. Bhatt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
分享论文
